Ghidurile ESC - Media Med Publicis

Ghiduri ale Societatii Europene de Cardiologie
2005;352:20-28.
445. Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di Sciascio G.
Randomized trial of atorvastatin for reduction of myocardial damage
during coronary intervention: results from the ARMYDA (Atorvastatin
for Reduction of MYocardial Damage during Angioplasty) study.
Circulation 2004; 110:674-678.
446. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C et al.
Efficacy and safety of cholesterol-lowering treatment: prospective
meta-analysis of data from 90,056 participants in 14 randomised trials
of statins. Lancet 2005;366:1267-1278.
447. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC et al.
Intensive lipid lowering with atorvastatin in patients with stable coro
nary disease. N Engl J Med 2005;352:1425-1435.
448. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ,
Holme I et al. High-dose atorvastatin versus usual-dose simvastatin for
secondary prevention after myocardial infarction: the IDEAL study: a
randomized controlled trial. JAMA 2005;294:2437-2445.
449. Wierzbicki AS. Ezetimibe: a new addition to lipid-lowering therapy. IntJ
Clin Pract 2003; 57:653-655.
450. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB et al.
Gemfibrozil for the secondary prevention of coronary heart disease in
men with low levels of high-density lipoprotein cholesterol. Veterans
Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study
Group. N Engl J Med 1999; 341:410-418.
451. Farnier M. Combination therapy with an HMG-CoA reductase inhibitor
and a fibric acid derivative: a critical review of potential benefits and
drawbacks. Am J Cardiovasc Drugs 2003;3:169-178.
452. Robins SJ, Rubins HB, Faas FH, Schaefer EJ, Elam MB, Anderson JWet al.
Insulin resistance and cardiovascular events with low HDL cholesterol:
the Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care
2003;26:1513-1517.
453. Prueksaritanont T, Tang C, Qiu Y, Mu L, Subramanian R, Lin JH. Effects of
fibrates on metabolism of statins in human hepatocytes. Drug Metab
Dispos 2002;30:1280-1287.
454. Pan WJ, Gustavson LE, Achari R, Rieser MJ, Ye X, Gutterman C et al.
Lack of a clinically significant pharmacokinetic interaction between
fenofibrate and pravastatin in healthy volunteers. J Clin Pharmacol
2000;40:316-323.
455. Keech A, Simes RJ, Barter P, Best J, Scott R, Takinen MR, Foreder P, Pillai A,
Davis T, Glasziou P, Drury P, Kesaniemi YA, Sullivan D, Hunt, Colman D,
d'Emden P, M.Whiting M, Ehnholm C, Laakso M, FIELD study investigators.
Effects of long-term ffenofibrate therapy on cardiovascular events in 9795
people with type 2 diabetes mellitus (the FIELD study): randomised con
trolled trial. Lancet 2005;366:1829-1831.
456. Brousseau ME, Schaefer EJ, Wolfe ML, Blodon LT, Digenio AG, Clark RW,
Manuscu JP, Rader DJ. Effects of an inhibitor of cholesteryl ester trans
fer protein on HDL cholesterol. N Engl J Med 2004;350:1491-1494.
457. Turnbull F. Effects of different blood-pressure-lowering regimens on
major cardiovascular events: results of prospectively-designed over
views of randomised trials. Lancet 2003;362:1527-1535
458. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood
pressure reduction: a quantitative overview updated until 1 March
2003. J Hypertens 2003;21:1055-1076.
459. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH
et al. Health outcomes associated with various antihypertensive
therapies used as first-line agents: a network meta-analysis. JAMA
2003;289:2534-2544.
460. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an
angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular
events in high-risk patients. The Heart Outcomes Prevention
Evaluation Study Investigators. N Engl J Med 2000;342:145-153.
461. Fox KM. Efficacy of perindopril in reduction of cardiovascular events
among patients with stable coronary artery disease: randomised,
double-blind, placebo-controlled, multicentre trial (the EUROPA
study). Lancet 2003;362:782-788.
462. Gustafsson I T-PC, Kober L, Gustafsson F HP. Effect of the angiotensinconverting
enzyme inhibitor trandopril on mortality and morbidity in
diabetic patients with left ventricular dysfunction after acute myocardial
infarction. Trace Study Group. 1999;34:83-89.
463. Luft FC. Recent clinical trial highlights in hypertension. Curr Hypertens
Rep 2001;3:133-138.
464. Svensson P, de Faire U, Sleight P, Yusuf S, Ostergren J. Comparative
effects of ramipril on ambulatory and office blood pressures: a HOPE
Substudy. Hypertension 2001;38:E28-E32.
465. Daly CA, Fox KM, Remme WJ, Bertrand ME, Ferrari R, Simoons ML. The
effect of perindopril on cardiovascular morbidity and mortality in
patients with diabetes in the EUROPA study: results from the PERSUADE
substudy. Eur Heart J 2005;26:1369-1378.
466. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific rel
evance of usual blood pressure to vascular mortality: a meta-analysis
of individual data for one million adults in 61 prospective studies.
Lancet 2002;360:1903-1913.
467. Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D et al.
Effect of antihypertensive agents on cardiovascular events in patients
with coronary disease and normal blood pressure: the CAMELOT study:
a randomized controlled trial. JAMA 2004; 292:2217-2225.
468. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L et al.
Outcomes in hypertensive patients at high cardiovascular risk treated
with regimens based on valsartan or amlodipine: the VALUE randomised
trial. Lancet 2004;363:2022-2031.
469. Poulter NR, Wedel H, Dahlof B, Sever PS, Beevers DG, Caulfield M et al.
Role of blood pressure and other variables in the differential cardio
vascular event rates noted in the Anglo-Scandinavian Cardiac
Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet
2005;366:907-913.
470. Staessen J, Birkenhager WH. Evidence that new antihypertensives are
superior to older drugs. Lancet 2005;366:869-871.
471. Jackson R, Lawes CM, Bennett DA, Milne RJ, Rodgers A. Treatment with
drugs to lower blood pressure and blood cholesterol based on an individ
ual's absolute cardiovascular risk. Lancet 2005;365:434-441.
472. Lonn EM, Yusuf S, Jha P, Montague TJ, Teo KK, Benedict CR et al.
Emerging role of angiotensin-converting enzyme inhibitors in cardiac
and vascular protection. Circulation 1994;90:2056-2069.
473. PfefferMA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP
et al. Valsartan, captopril, or both in myocardial infarction complicated
by heart failure, left ventricular dysfunction, or both. N Engl J Med
2003;349:1893-1906.
474. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ et al.
Effects of candesartan in patients with chronic heart failure and pre
served left-ventricular ejection fraction: the CHARM-Preserved Trial.
Lancet 2003;362:777-781.
475. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B et al.
Randomized trial of estrogen plus progestin for secondary prevention
of coronary heart disease in postmenopausal women. Heart and
Estrogen/progestin Replacement Study (HERS) Research Group. JAMA
1998;280:605-613.
476. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M
et al. Cardiovascular disease outcomes during 6.8 years of hormone
therapy: Heart and Estrogen/progestin Replacement Study follow-up
(HERS II). JAMA 2002;288:49-57.
477. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C,
Stefanick ML et al. Risks and benefits of estrogen plus progestin in
healthy postmenopausal women: principal results From the Women's
Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
478. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL et al.
Estrogen plus progestin and the risk of coronary heart disease. N Engl
JMed2003;349:523-534.
479. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal
hormone therapy: annual trends and response to recent evidence.
JAMA 2004; 291:47- 53.
480. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical
trials in heart disease. I. Treatments following myocardial infarction.
JAMA 1988; 260:2088-2093.
481. Freemantle N, Urdahl H, Eastaugh J, Hobbs FD. What is the place of
beta-blockade in patients who have experienced a myocardial infarction
with preserved left ventricular function? Evidence and (mis)interpreta
tion. Prog Cardiovasc Dis 2002;44:243-250.
482. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a
wise choice? Lancet 2004;364:1684-1689.
483. Hjemdahl P, Eriksson SV, Held C, Forslund L, Nasman P, Rehnqvist N.
Favourable long term prognosis in stable angina pectoris: an extended
follow up of the angina prognosis study in Stockholm (APSIS). Heart
2006;92(2):177-182. [EPub ahead of print June 10, 2005]
484. Pepine CJ, Cohn PF, Deedwania PC, Gibson RS, Handberg E, Hill JA et al.
Effects of treatment on outcome in mildly symptomatic patients with
ischemia during daily life. The Atenolol Silent Ischemia Study (ASIST).
Circulation 1994; 90:762-768.
485. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL
Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF).
Lancet 1999;353:2001-2007.
486. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised
trial. Lancet 1999;353:9-13.
487. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM et al.
61